Navigation Links
Taking the wrinkles out of motoneuronal disease

A winner of UniQuest's 2006 Trailblazer innovation competition, Dr Frederic Meunier, is developing a treatment for motoneuronal diseases based on modifying botox –the popular anti-wrinkle treatment.

Motoneuronal diseases cause a degeneration of the nerve pathways controlling muscle activity. The diseases are severe and physically debilitating disorders which lead toprogressive weakness and wasting of muscles. Many of the diseases are incurable.

Dr Meunier is developing botox to selectively deliver drugs to motoneurons to directly treatmotorneuron diseases.

"I first became interested in investigating neurotoxins because they are fantastic moleculartools to dissect synaptic mechanisms," Dr Meunier said.

"The aim of our lab is to understand the molecular mechanism underlying neuronal communication. The legacy of millions of years of evolution and competition between venomous species has resulted in deadly neurotoxins capable of blocking neuronal communication. I am using our knowledge of the mode of action of these neurotoxins to design a selective motoneuron delivery system that could change our way of treating motoneuronal diseases."

Dr Meunier's innovative research caught the attention of UQ's main commercialisation company, UniQuest Pty Ltd, which runs the annual Trailblazer competition.

UniQuest Managing Director David Henderson said the Trailblazer judges were impressed by Dr Meunier's research and the opportunities surrounding it.

"The therapeutic applications of this research are important, as it could help prevent or cure motoneuronal diseases," Mr Henderson said.

"Also, the research potentially has important applications for the treatment of other diseases."


'"/>

Source:Research Australia


Page: 1

Related biology news :

1. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
2. Taking Aim With Nanoparticle PEBBLEs
3. Taking the piste out of Alpine vegetation
4. Taking a flying jump
5. Taking a bite out of a fellow worker helps wasps recruit new foragers
6. Taking evolutions temperature: Researchers pinpoint the energy it takes to make a species
7. Taking chips to the next level of gene hunting
8. Cancer vaccines -- Taking a jab at cancer by stimulating the immune system
9. Neuronal traffic jam marks early Alzheimers disease
10. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
11. U of M researcher examines newly emerging deadly disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology: